Back

Decoding Plasticity Regulators and Transition Trajectories in Glioblastoma with Single-cell Multiomics

Saraswat, M.; Rueda-Gensini, L.; Heinzelmann, E.; Gracia, T.; Memi, F.; de Jong, G.; Straub, J.; Schloo, C.; Hoffmann, D. C.; Jung, E.; Kindinger, T.; Weigel, B.; Lim, B.; Weil, S.; Gould, O.; Mair, R.; Mikulik, K.; Rohbeck, M.; Wick, W.; Winkler, F.; Bayraktar, O. A.; Stegle, O.; Mall, M.

2025-05-13 cancer biology
10.1101/2025.05.13.653733 bioRxiv
Show abstract

Glioblastoma (GB) is one of the most lethal human cancers, marked by profound intratumoral heterogeneity and near-universal treatment resistance. Cellular plasticity, the capacity of cancer cells to transition between phenotypic states, drives GB progression and resistance. However, the regulatory logic that permits or restricts specific state transitions remains poorly understood. Here, we integrated single-nucleus RNA and chromatin accessibility multi-ome profiles from over one million cells across primary IDH-wildtype GBs and developed scDORI, a scalable deep-learning framework to infer enhancer-driven gene regulatory networks (eGRNs) at single-cell resolution. Our analysis revealed a structured hierarchy of GB cell states governed by distinct regulatory programs, with marked variability in epigenetic plasticity that enables or constrains transitions. Neuronal-like tumor cells emerge as a low plasticity state that deploys active repression, in contrast to more permissive progenitor-like and astrocytic states. We identified the neuronal-like state-specific repressor MYT1L as a key regulator that silences master transcription factors of alternative states. MYT1L gain-of-function in patient-derived GB cells reduced chromatin accessibility, induced neuronal-like identity, and restricted proliferation and invasion in vivo, whereas loss-of-function reactivated plasticity and accelerated malignant features. Our findings delineate the epigenetic architecture and associated transcriptional master regulators that shape GB state trajectories, and establish safeguard repressors such as MYT1L as potential therapeutic targets to constrain malignant plasticity.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.